fosaprepitant iv brand names and other generic formulations include:
No brand names available
ibrutinib oral brand names and other generic formulations include:
Imbruvica Oral
fosaprepitant iv and ibrutinib oral
fosaprepitant iv increases levels of ibrutinib oral by altering drug metabolism. Avoid taking this combination, ibrutinib blood concentrations may increase; your doctor may consider alternatives. If unable to avoid, your doctor may decrease ibrutinib dose to 140 mg/day.
fosaprepitant iv and ibrutinib oral
fosaprepitant iv increases levels of ibrutinib oral by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for ≤7 days), interrupt ibrutinib therapy until strong CYP3A4 inhibitor is discontinued.
Check for more interactions with the Drug Interaction Checker
Drug Interaction Categories
Contraindicated
Never use this combination of drugs because of high risk for dangerous interaction
Serious
Potential for serious interaction; regular monitoring by your doctor required or alternate medication may be needed
Significant
Potential for significant interaction (monitoring by your doctor is likely required)
Minor
Interaction is unlikely, minor, or nonsignificant